ACELYRIN, Inc. financial data

Symbol
SLRN on Nasdaq
Industry
Pharmaceutical Preparations
Location
4149 Liberty Canyon Rd., Agoura Hills, CA
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1K %
Debt-to-equity 11.2 %
Return On Equity -46.1 % +77.1%
Return On Assets -41.5 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 99.8M shares +2.68%
Common Stock, Shares, Outstanding 99.6M shares +3498%
Entity Public Float 1.46B USD
Common Stock, Value, Issued 1K USD 0%
Weighted Average Number of Shares Outstanding, Basic 99.2M shares +52.1%
Weighted Average Number of Shares Outstanding, Diluted 99.2M shares +52.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 292M USD +28.3%
General and Administrative Expense 83M USD +152%
Operating Income (Loss) -375M USD -44%
Net Income (Loss) Attributable to Parent -300M USD -26.7%
Earnings Per Share, Basic 2.36 USD/shares -115%
Earnings Per Share, Diluted 2.36 USD/shares -115%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 128M USD -76.9%
Cash, Cash Equivalents, and Short-term Investments 636M USD -22.7%
Assets, Current 648M USD -21.9%
Property, Plant and Equipment, Net 1.51M USD -23.5%
Operating Lease, Right-of-Use Asset 1.1M USD -14.3%
Assets 652M USD -22%
Accounts Payable, Current 40.7M USD +346%
Liabilities, Current 82.5M USD +152%
Operating Lease, Liability, Noncurrent 1.07M USD -18.3%
Liabilities 83.5M USD +145%
Accumulated Other Comprehensive Income (Loss), Net of Tax -167K USD -480%
Retained Earnings (Accumulated Deficit) -609M USD -96.8%
Stockholders' Equity Attributable to Parent 568M USD -29.1%
Liabilities and Equity 652M USD -22%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -57.3M USD -126%
Net Cash Provided by (Used in) Financing Activities 2.81M USD
Net Cash Provided by (Used in) Investing Activities 101M USD +112%
Common Stock, Shares Authorized 790M shares 0%
Common Stock, Shares, Issued 99.6M shares +2.44%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 46.4M USD +110%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 129M USD -76.9%
Deferred Tax Assets, Valuation Allowance 98.7M USD +316%
Deferred Tax Assets, Gross 99M USD +317%
Operating Lease, Liability 1.31M USD -3.82%
Payments to Acquire Property, Plant, and Equipment 55K USD -76.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -300M USD -26.8%
Lessee, Operating Lease, Liability, to be Paid 1.66M USD -11.5%
Property, Plant and Equipment, Gross 1.74M USD -13.2%
Operating Lease, Liability, Current 240K USD +362%
Lessee, Operating Lease, Liability, to be Paid, Year Two 398K USD +3.11%
Lessee, Operating Lease, Liability, to be Paid, Year One 386K USD +2.93%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 353K USD -31.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 409K USD +2.76%
Deferred Tax Assets, Operating Loss Carryforwards 19.6M USD +217%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Unrecognized Tax Benefits 2.35M USD +355%
Lessee, Operating Lease, Liability, to be Paid, Year Four 280K USD -31.5%
Additional Paid in Capital 1.18B USD +6.05%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 55K USD
Deferred Tax Assets, Net of Valuation Allowance 252K USD
Share-based Payment Arrangement, Expense 62M USD +250%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares